-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS-1596 tablets, agreeing to carry out clinical trials of this product for weight management indications and type 2 diabetes.

Zhitongcaijing·09/21/2026 09:01:04
Listen to the news
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS-1596 tablets, agreeing to carry out clinical trials of this product for weight management indications and type 2 diabetes.